nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Causality Assessment for Suspected DILI During Clinical Phases of Drug Development
|
Regev, Arie |
|
2014 |
37 |
supplement-1 |
p. 47-56 |
artikel |
2 |
Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges
|
Senior, John R. |
|
2014 |
37 |
supplement-1 |
p. 9-17 |
artikel |
3 |
Liver Safety Assessment in Special Populations (Hepatitis B, C, and Oncology Trials)
|
Kullak-Ublick, Gerd A. |
|
2014 |
37 |
supplement-1 |
p. 57-62 |
artikel |
4 |
Liver Safety Assessment: Required Data Elements and Best Practices for Data Collection and Standardization in Clinical Trials
|
Avigan, Mark I. |
|
2014 |
37 |
supplement-1 |
p. 19-31 |
artikel |
5 |
Methodology to Assess Clinical Liver Safety Data
|
Merz, Michael |
|
2014 |
37 |
supplement-1 |
p. 33-45 |
artikel |
6 |
The Clinical Liver Safety Assessment Best Practices Workshop: Rationale, Goals, Accomplishments and the Future
|
Watkins, Paul B. |
|
2014 |
37 |
supplement-1 |
p. 1-7 |
artikel |